www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/19821

Title: Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
Authors: Driessen, Johanna H. M.
van Onzenoort, Hein A. W.
Starup-Linde, Jakob
Henry, Ronald
Neef, Cees
van den Bergh, Joop
Vestergaard, Peter
de Vries, Frank
Burden, Andrea M.
Issue Date: 2015
Publisher: WILEY-BLACKWELL
Citation: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24 (10), p. 1017-1025
Abstract: IntroductionDipeptidyl peptidase-4 inhibitors (DPP4-Is) are a new class of anti-hyperglycemic drugs which might have a potential beneficial effect on bone metabolism. Data on the effect of DPP4-I use and fracture risk is limited and conflicting. The aim of the present study was to investigate the association between use of DPP4-Is and fracture risk. MethodsA case-control study was conducted using data from the Danish National Health Service. Cases were those who sustained a fracture, and controls were those without a fracture during the study period (2007-2011), all aged 18years and older. Conditional logistic regression estimated the odds ratios of fracture with current use of DPP4-I use. Analyses were adjusted for comorbidities and recent drug use. ResultsAmong the cases there were 6993 current non-insulin anti-diabetic drug (NIAD) users (excluding incretin users) and 643 DPP4-I users. There were 7209 NIAD users (excluding incretin users) among the controls and 707 DPP4-I users. Current DPP4-I use was not associated with risk of any fracture (adjusted [adj.] OR: 0.97, 95% CI: 0.79-1.18) or major osteoporotic fracture (adj. OR: 0.96, 95% CI: 0.72-1.28). Stratification of current DPP4-I use to cumulative and average daily dose did not show an association. ConclusionsIn a population-based case-control study we identified that short-term use of DPP4-I was not associated with fracture risk as compared to users of other anti-hyperglycemic drugs. Additionally, results suggest that increasing daily dose and cumulative DPP4-I exposure were not associated with fracture risk. However, more research is needed to assess the effect of long-term DPP4-I use on the risk of fracture. Copyright (c) 2015 John Wiley & Sons, Ltd.
Notes: [Driessen, Johanna H. M.; de Vries, Frank; Burden, Andrea M.] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands. [Driessen, Johanna H. M.; Neef, Cees; de Vries, Frank; Burden, Andrea M.] Care & Publ Hlth Res Inst, Maastricht, Netherlands. [Driessen, Johanna H. M.; van Onzenoort, Hein A. W.; Neef, Cees; de Vries, Frank; Burden, Andrea M.] Maastricht Univ Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands. [van Onzenoort, Hein A. W.] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL-6525 ED Nijmegen, Netherlands. [Starup-Linde, Jakob; Vestergaard, Peter] Aalborg Univ, Dept Clin Med, Aalborg, Denmark. [Starup-Linde, Jakob] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, DK-8000 Aarhus, Denmark. [Henry, Ronald] Maastricht Univ, Med Ctr, Dept Med, NL-6200 MD Maastricht, Netherlands. [Henry, Ronald] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands. [van den Bergh, Joop] Maastricht Univ, Med Ctr, Dept Internal Med, NL-6200 MD Maastricht, Netherlands. [van den Bergh, Joop] Univ Hasselt, Biomed Res Inst, Hasselt, Belgium. [Vestergaard, Peter] Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark. [de Vries, Frank] Southampton Gen Hosp, MRC Epidemiol Lifecourse Unit, Southampton SO9 4XY, Hants, England.
URI: http://hdl.handle.net/1942/19821
DOI: 10.1002/pds.3837
ISI #: 000362408900002
ISSN: 1053-8569
Category: A1
Type: Journal Contribution
Validation: ecoom, 2016
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version104.79 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.